Contact:
At RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992
or
At the Financial
Relations Board:
Analyst Inquiries:
Leslie Loyet
312.640.6672
or
General Inquiries
Kathy Waller
312.640.6696 |
CORRECTING and REPLACING RegeneRx to Present at Biotechnology Industry Organization's 2006 Business Forum
CORRECTING and REPLACING RegeneRx to Present at Biotechnology Industry Organization's 2006 Business Forum
April 3, 2006 — Bethesda, Md
In BW5438 issued April 3, 2006: First sentence of release should read: Tuesday, April 11, 2006 (sted Tuesday, April 10, 2006).
The corrected release reads:
REGENERX TO PRESENT AT BIOTECHNOLOGY INDUSTRY ORGANIZATION'S 2006 BUSINESS FORUM
RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN) announced today that its President and Chief Executive Officer, J.J. Finkelstein, will be a presenter at the Biotechnology Industry Organization's (BIO) 2006 Business Forum on Tuesday, April 11, 2006 at 9:30 a.m. in Chicago. Mr. Finkelstein will highlight the company's technology platform, clinical program, and provide an update on RegeneRx's plans for its ophthalmic and cardiac clinical trials targeted for later this year. CEO's from over 240 biotechnology and pharmaceutical companies from around the world will make business development-focused presentations at the Business Forum discussing their companies' technologies and business strategies. There are over 18,000 biotechnology professionals expected to attend the four-day meeting.
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43-amino acid peptide, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore RegeneRx is developing TB4 as a therapeutic platform. RegeneRx holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, and septic shock. RegeneRx is currently sponsoring three Phase II chronic dermal wound healing clinical trials and has additionally targeted ophthalmic and cardiac trials in 2006 as part of its ongoing clinical development program.
Safe Harbor Statement
The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development of TB4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.
For more information please visit RegeneRx's web site at www.regenerx.com
SOURCE: RegeneRx Biopharmaceuticals, Inc.  Back To 2006 Press Release Archives
|
